Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

Company Overview

Ironwood Pharmaceuticals, Inc. is a gastrointestinal-focused biopharmaceutical company that discovers, develops, and commercializes medicines for gastrointestinal diseases. The company concentrates on conditions affecting the digestive system, including disorders with substantial unmet medical needs.

Ironwood’s principal commercial product is LINZESS (linaclotide), a prescription treatment for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. In the United States, LINZESS is marketed through a collaboration with AbbVie, while it is marketed in many international markets under the name CONSTELLA through a collaboration with the healthcare business of AstraZeneca and other regional partners.

Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood has expanded its development activities through internal research, partnerships, and acquisitions. The company’s pipeline has included additional therapies for gastrointestinal and related disorders, including programs obtained through its acquisition of VectivBio. Ironwood’s products and development programs serve patients in the United States and selected international markets through its commercial operations and collaboration network. Tom McCourt serves as the company’s chief executive officer.

Key Stats

• Today's Range: $3.51 to $3.63
• 50-Day Range: $3.59 to $4.53
• 52-Week Range: $1.43 to $5.78
• Volume: 294,193 shs
• Average Volume: 2.96 million shs
• Market Capitalization: $595.69 million
• P/E Ratio: 4.68
• Dividend Yield: N/A
• Price Target: $6.23
• Consensus Rating: Moderate Buy

Ironwood Pharmaceuticals Stock Analysis - MarketRank™

Ironwood Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 307th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ironwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 2 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Ironwood Pharmaceuticals has a consensus price target of $6.23, representing about 73.6% upside from its current price of $3.59.

Amount of Analyst Coverage

Ironwood Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ironwood Pharmaceuticals are expected to decrease in the coming year, from $1.10 to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ironwood Pharmaceuticals is 4.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 35.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ironwood Pharmaceuticals is 4.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 202.90.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.39% of the float of Ironwood Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 6.19.

Change versus previous month

Short interest in Ironwood Pharmaceuticals has recently decreased by 16.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ironwood Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Ironwood Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.64

News Sentiment

Ironwood Pharmaceuticals has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Ironwood Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

6 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ironwood Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.30% of the stock of Ironwood Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Ironwood Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IRWD
• CIK: 1446847
• Web: www.ironwoodpharma.com
• Phone: (617) 621-7722
• Fax: 617-494-0480
• Employees: 100
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Ironwood Pharmaceuticals: $6.23
• High Price Target: $10.00
• Low Price Target: $3.70
• Potential Upside/Downside: +72.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.77
• Trailing P/E Ratio: 4.68
• Forward P/E Ratio: 3.28
• P/E Growth: N/A
• Net Income: $24.02 million
• Net Margins: 33.36%
• Pretax Margin: 53.27%
• Return on Equity: -58.38%
• Return on Assets: 34.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.06
• Quick Ratio: 6.06

Sales & Book Value

• Annual Sales: $296.15 million
• Price / Sales: 2.01
• Cash Flow: $0.25 per share
• Price / Cash Flow: 14.61
• Book Value: ($1.61) per share
• Price / Book: -2.24

Miscellaneous

• Outstanding Shares: 165,240,000
• Free Float: 149,873,000
• Market Cap: $595.69 million
• Optionable: Optionable
• Beta: 0.21